Retina Synthesis

We discuss management of eyes with both geographic atrophy and neovascular AMD with Dr. Ted Leng of the Byers Eye Institute, Stanford University School of Medicine

We review the 6 month results of the Davio 2 trial of  the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.

We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates

We discuss the promising phase I results of the Helios trial studying AXPAXLI  TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.

We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy  with Dr. Michael Singer of San Antonio, Texas

We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.

We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.

We discuss the use of a novel bispecific anti-VEGF Anti IL-6 Antibody Biopolymar Conjugate for the treatment of DME with Dr. Mark R. Barakat of Phoenix, AZ.

We discuss the occurrence of retinal vasculitis following pegcetcoplan therapy of geographic atrophy with Dr. Andrew Witkin of the New England Eye Center, Tufts University School of Medicine

We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.

We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.

We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

We discuss the unique results of the Annexon geographic atrophy Phase I clinical trial with Dr. Roger Goldberg of Bay Area Retina Associates, Walnut Creek, California

We review the latest diagnostic and therapeutic approaches for retinoblastoma with Dr. Jesse Berry, Associate Professor of Ophthalmology, Children's Hospital Los Angeles.

We discuss the feasibility of using home OCT vs. a treat and extend approach in a clinical trial of faricimab in neovascular AMD with Dr. Kevin Blinder of the Retina Institute in Saint Louis, Mo and Profesor of Ophthalmology at Washington University School of Medicine.

We discuss the characteristics of eyes with the best visual outcomes in the Davio trial of TKI EY-1901 with Dr. Philip Storey of the Austin Retina Associates, Austin, Texas.

We discuss a post-hoc study comparing the efficacy of Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) with Paul Hahn, MD, PhD, of NJ Retina.

We discuss a comparative trial of preventive therapy for non-proliferative retinopathy vs. ad hoc treatment of disease complications with Dr. Hani Salehi-Had of Retina Associates of Southern California, Huntington Beach, California.

We discuss the latest information on phase 2 trials of gene therapy for x-linked retinitis pigmentosa with Dr. Nadia Waheed, Chief Medical Officer of Beacon Therapeutics and Associate Professor of Ophthalmology at the New England Eye Center, Tufts University School of Medicine.

We discuss the use of optogenetics for the treatment of inherited retinal degenerations with Dr. Jose Sahel, Chairman and Distinguished Professor of Ophthalmology at the University of Pittsburgh School of Medicine.

We discuss the importance of intensive therapy of DME, when using aflibercept for DME, as suggested by a review of real world cases from the Vestrum  data base, with Dr. Ferhina Ali, Assistant Professor of Ophthalmology, New York Medical College

We discuss the use of a topical agent for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Research, Sierra Eye Associates, Associate Clinical Professor of Ophthalmology, University Nevada School of Medicine, Reno.

We review novel approaches for the treatment of intermediate AMD, with Dr. Barry Kuppermann, Director Gavin Herbert Eye Institute, Chairman Department of Ophthalmology, University of California Irvine, Steinert Endowed Chair.

 In our latest update, we discuss safety issues associated with retinal gene therapy with Professor Glenn Yiu of the University of California School of Medicine.

We discuss the use of a novel oral agent for the treatment of diabetic retinopathy with David R. Lally, MD, Director of Research, New England Retina Consultants, Springfield, MA

We discuss intravitreal gene therapy with a new agent, 4D-150 with Veeral Sheth, MD, MBA  Assistant Clinical Professor of Ophthalmology University of Illinois at Chicago.

We discuss the use of optogenetics in the treatment of retinal degenerations with Dr. Michael Singer, Adjunct Professor of Ophthalmology, University of Texas Health Science Center, San Antonio.

We discuss retinal drying in diabetic macular edema using the Iluvien implant with Dr. Michael Singer, Adjunct Professor, University of Texas Health Science Center, San Antonio.

We discuss the use of blockade of VEGF C and D in the treatment of neovascular AMD with Dr. Dante Pieramici, California Retina Research Foundation, California Retina Consultants.

We discuss the use of a novel treatment approach, senolytic therapy, for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Professor, USC Roski Eye Institute.

We discuss the use of the PDS in the treatment of diabetic retinopathy and diabetic macular edema with Professor Carl Regillo of the Wills Eye Hospital.

Dr. Eugene de Juan, winner of this year's ASRS Pyron Award, joins us to discuss his career highlights. Dr. de Juan is CEO of Forsight Labs and Professor of Ophthalmology, University of California, San Francisco.

In our latest update, We discuss the use of surgical sub retinal gene therapy for neovascular AMD with RGX-314. Our guest Dr. Courtney Crawford, Ft. Worth, Texas.

We discuss the use of an improved implantable telescope as a low vision aid in patients with macular disease with Dr. David Almeida, Erie Retina Research.

We discuss the prevention of vision loss in the Gather 2 trial of IZERVAY with Dr. Carl Danzig of the Rand Eye Institute, Pompano Beach, Florida

We discuss a 30-Month Outcome with Pegcetacoplan for the Treatment of Geographic Atrophy with Nathan Steinle MD, California Retina Consultants, Santa Barbara, California.

We discuss the latest information on Safety & Efficacy in Clinic and Clinical Trials with Cedric Francois, MD, PhD.

We discuss the latest information on the use of faricimab in neovascular AMD with Dr. Yasha Modi, Associate Professor of Ophthalmology, NYU Langone Medical Center.

We discuss the use of high dose aflibercept for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor, Roski Eye Institute of USC.

We discuss the latest information on the use of pegcetacoplan for geographic atrophy in AMD with Dr. Dilsher Dhoot, California Retinal Consultants.

We discuss the use of a novel drug (tyrosine kinase inhibitor) and novel delivery system (hydrogel) for the treatment of neovascular AMD with Dr. Peter Kaiser of the Cleveland Clinic.

We discuss the use of biosimilar drugs for retinal diseases with Dr. Arghavan Almony, author of definitive monograph of these agents.

In our latest update, we discuss the relative drying effects of faricimab and aflibercept in the treatment of diabetic macular edema with Dr. Roger Goldberg.

In our latest update, we discuss the use of artificial intelligence in the management of geographic atrophy with Professor Pearse Keane, Moorfields Eye Hospital, London.

In our latest update, we discuss the use of molecular techniques in the management of uveal melanoma with Dr. William Harbour, Professor and Chair, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.

We discuss the results of clinical trials studying  the use of faricimab in the treatment of retinal venous occlusion with Dr. Ramin Tadayoni, Professor of Ophthalmology University of Paris.

We review the one year results of a clinical trial using high dose aflibercept (8mg) for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Clinical Professor of Ophthalmology, USC Roski Eye Institute

We the discuss the use of wide field OCT angiography in the management of diabetic retinopathy, retinal vein occlusion, and pediatric retinal disease with Dr. Amir Kashani, Associate Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine

We review the use of anti-VEGF therapy for retinopathy of prematurity and in particular, the results of a clinical trial employing aflibercept with Dr. Darius Moshfeghi, Professor of Ophthalmology, Director of the Retina Service, Byers Eye Institute, Stanford University School of Medicine.

We discuss the use of home OCT and artificial intelligence in the management of anti-VEGF therapy of neovascular AMD with Dr. Anat Loewenstein, Director, Department of Ophthalmology, Tel Aviv Medical Center, Israel.

We discuss the use of suprachoroidal triamcinolone for the treatment of macular edema with Dr. Steven Yeh, Truhlsen Chair of Ophthalmology, University of Nebraska School of Medicine.